Stem Cell NK Differentiation Kit for TMZ-Resistant GBM Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for inducing stem cells to differentiate into natural killer (NK) cells are inefficient and complex, and there is a need for effective treatments for TMZ-resistant glioblastoma (GBM) due to high heterogeneity and the blood-brain barrier, with current immunotherapy not providing breakthroughs.
Innovation Solution
A kit comprising specific culture media with activators and inhibitors to induce stem cells into NK cells, and a combination therapy using NK cells and temozolomide (TMZ) for TMZ-resistant GBM.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If existing methods for inducing stem cells to differentiate into NK cells are used, then NK cells can be produced, but the differentiation efficiency is low and NK cell yield is limited
Solution Approach 1:
The patent changes the biochemical parameters of the culture medium by adding specific factors (IL-2, IL-15, IL-21, FLT3L, SCF, VEGF, BMP4) and inhibitors (PD-0325901, SB431542) to optimize the differentiation process. This resolves the contradiction by adjusting medium composition to simultaneously improve both differentiation efficiency and NK cell yield.
Solution Approach 2:
The patent performs preliminary actions by pre-differentiating stem cells into hematopoietic progenitor cells before final NK cell differentiation. This staged approach with preliminary hematopoietic commitment improves the efficiency and yield of subsequent NK cell generation.
2Adaptability or versatility
If stem cells are differentiated into NK cells for immunotherapy, then treatment options expand, but the process becomes complex and time-consuming
Solution Approach 1:
The patent segments the differentiation process into distinct stages: hematopoietic progenitor cell differentiation followed by NK cell differentiation. This segmentation makes the complex process more manageable and controllable, reducing operational complexity while maintaining versatility.
Solution Approach 2:
The patent employs periodic action by using sequential culture media changes and staged differentiation protocols. The process alternates between different culture conditions and time points, making the complex differentiation process more systematic and easier to execute.
3Reliability
If NK cells are used for TMZ-resistant GBM treatment, then therapeutic efficacy improves, but the cost and manufacturing complexity increase
Solution Approach 1:
The patent creates a universal differentiation protocol that can produce NK cells from various stem cell sources (pluripotent stem cells and hematopoietic stem cells). This multi-functional approach ensures reliable therapeutic efficacy while standardizing the manufacturing process to reduce complexity.
Data Source
Figure 1A~1B
Figure 2A~2G
Figure 3A~3F
AI summary
The present invention relates to the field of biotechnology, and provides a kit and method for inducing stem cells to differentiate into natural killer (NK) cells, and a use of the kit. In the kit, a culture medium having clear chemical components, chemical small molecules, and cytokines are used. The kit does not involve substances such as serum which are easy to cause unstable factors such as batch differences, is cheaper in price than a known commercial differentiation culture medium, and reduces the differentiation period. The present invention further provides a pharmaceutical composition and method for treating glioblastoma (GBM), particularly drug-resistant GBM, and a use of the pharmaceutical composition. Specifically, the present invention relates to treatment for GBM by combining immune cells and a chemotherapy drug. More specifically, the present invention relates to synergistic treatment for TMZ drug-resistant GBM by combining NK cells and TMZ.